Experimental gene injection targets dry AMD

NCT ID NCT03846193

Terminated Disease control Sponsor: Gyroscope Therapeutics Limited Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a gene therapy called GT005 for dry age-related macular degeneration (AMD), a leading cause of vision loss. The therapy delivers a working gene to the retina via a single injection. The study enrolled 56 people and focused on safety and dosing, but was terminated early. If it works, it could offer a one-time treatment to slow vision loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GT005 (a gene therapy that delivers a working copy of the complement factor I gene via a single injection under the retina)
What this could lead to: If successful, this could lead to a one-time gene therapy that slows or stops vision loss in people with dry age-related macular degeneration.
What could go wrong: This was a very early (Phase 1/2) trial with only 56 participants, and it was terminated early. The therapy involves a surgical injection into the eye, which carries risks like infection or retinal damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRY AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration dry age related macular degeneration eye disorder Geographic Atrophy macular degeneration primary anetoderma retinal degeneration retinal disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

Bristol Eye Hospital

Bristol, United Kingdom
Cincinnati Eye Institute

Cincinnati, Ohio, 45242, United States
Manchester Eye Hospital

Manchester, United Kingdom
Mid-Atlantic Retina

Philadelphia, Pennsylvania, 19107, United States
Midwest Eye Institute

Indianapolis, Indiana, 46290, United States
Moorfields Eye Hospital

London, United Kingdom
Ophthalamic Consultants of Boston (OCB)

Boston, Massachusetts, 02114, United States
Oxford University Hospital

Oxford, United Kingdom
Pepose Vision Institute

Chesterfield, Missouri, 63017, United States
Retina Clinic London

London, W1G 7LA, United Kingdom
Sierra Eye Associates

Reno, Nevada, 89502, United States
Sunderland Eye Infirmary

Sunderland, United Kingdom
Wolfe Eye Clinic

West Des Moines, Iowa, 50266, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.